Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to obtain preliminary safety and tolerability data with
davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration
[FTLD] with predicted tau pathology, corticobasal degeneration syndrome [CBS] or progressive
supranuclear palsy [PSP]). The secondary objectives of this study are to obtain preliminary
data on short term changes (at 12 weeks) in a variety of clinical, functional and biomarker
measurements from baseline, including cerebrospinal fluid (CSF) tau levels, eye movements,
and brain MRI measurements.